January 22, 2018
Momentum is a force gained by moving objects – The iShares Nasdaq Biotechnology (IBB +0.89%), the SPDR S&P Biotech ETF (XBI +1.61%); the Health Care Select Sector SPDR ETF (XLV +0.06%) while the iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.16% in Monday’s pre-open
Unfortunately, other record gains have seen some losses with directionless pricing and diffused volatility are tainting the sentiment
We are also seeing decreases in volume and increased volatility
Outlook, precarious … as government shutdown continues even with JUNO’s upside at $18.43 or +27.18% pre-market
Pre-open indications: 1 SELL and 5 BUYs
January 16, 2018
XON is trading UP +$0.53 or +3.49% to $14.25
January 16, 2018
Pre-market, CAPR is UP +$0.15 or +8.43% - tell the real story! Think the CEO got a good deal from her :husband’s" CSMC lab, the additional cost to the research agreement is what and who is paying for the filings - CAPR!
January 12, 2018
Intrexon (XON) is up +$1.08
January 19, 2018
The sector opened neutral <19/19 and 2 flats>, was up at the mid-day <21/17 and 2 flats> and closed positive (21/18 and 1 flat)
While the IBB (+0.73%), XLV (+0.41%), XBI (+1.17%), IWM (+1.32%) with the NADAQ (+0.55%) were UP
What’s a good price for individual sector equities?
It’s still based on fundamental and speculative opinions which have major limits of their own.
Pre-open indications: 5 hits and 0 miss
Out and about: The Biostage (BSTG +$0.10) chronicles … don’t be fooled by surges!
January 9, 2018
HSGX had closed up + $0.02 to $2.24, the pre-market indication is +$0.08 or +3.57% - BUY
January 5, 2018
Takeda intends to acquire 100% of the securities with voting rights or giving access to voting rights of TiGenix not already owned by Takeda or affiliates at a price of EUR 1.78 per share in cash and an equivalent price in cash per American Depositary Share, warrant and convertible bond.
January 3, 2018
SGMO closed up +$1.15 or 7.01% to $17.55 with a pre-market indication is a positive +$0.60 or +3.39% after news of the company's $12 million collaboration with Pfizer (PFE) on a gene therapy for two neurodegenerative disorders, amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.